Skip to main content
. 2023 Jun 27;66(3):E310–E320. doi: 10.1503/cjs.017020

Fig. 1.

Fig. 1

Kaplan–Meier progression-free survival estimates (A) overall, (B) stratified by International Federation of Obstetrics and Gynecology (FIGO) stage, (C) stratified by residual disease after cytoreductive surgery, (D) stratified by treatment with platinum-based chemotherapy (chemo), (E) stratified by treatment with platinum-based chemotherapy in patients with stage I disease and (F) stratified by race.